111 related articles for article (PubMed ID: 3308067)
1. Multidrug resistance in ovarian cancer.
Fojo A; Hamilton TC; Young RC; Ozols RF
Cancer; 1987 Oct; 60(8 Suppl):2075-80. PubMed ID: 3308067
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic reversal of drug resistance in ovarian cancer.
Ozols RF
Semin Oncol; 1985 Sep; 12(3 Suppl 4):7-11. PubMed ID: 4048979
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
4. Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice.
Ford JM; Yang JM; Hait WN
Cancer Res; 1991 Jan; 51(1):67-72. PubMed ID: 1988108
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
Ozols RF; Masuda H; Hamilton TC
NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
10. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
12. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.
Zheng W; Li M; Lin Y; Zhan X
Biomed Pharmacother; 2018 Dec; 108():565-573. PubMed ID: 30243090
[TBL] [Abstract][Full Text] [Related]
14. Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications.
Ozols RF; Hamilton TC; Young RC
Prog Clin Biol Res; 1986; 223():173-85. PubMed ID: 3809199
[No Abstract] [Full Text] [Related]
15. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
16. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
17. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
Trendowski M; Christen TD; Acquafondata C; Fondy TP
BMC Cancer; 2015 Sep; 15():632. PubMed ID: 26357852
[TBL] [Abstract][Full Text] [Related]
18. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
19. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.
Lai GM; Ozols RF; Young RC; Hamilton TC
J Natl Cancer Inst; 1989 Apr; 81(7):535-9. PubMed ID: 2493524
[TBL] [Abstract][Full Text] [Related]
20. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
